Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28275576 | 0.94 | PARP1 (0.58) | PARP1TAAR1NR3C2CA1CA2 | |
| SCHEMBL4949653 | 0.80 | TAAR1 (0.67) | TAAR1NR1H2NR1H3AOC3ABCB1 | |
| SCHEMBL1568764 | 0.80 | NR3C2 (0.60) | PARP1TAAR1NR3C2MTNR1AMTNR1B | |
| SCHEMBL30080050 | 0.80 | TAAR1 (0.77) | TAAR1AOC3ABCB1 | |
| SCHEMBL723511 | 0.80 | TAAR1 (0.77) | TAAR1AOC3ABCB1 | |
| SCHEMBL9826497 | 0.80 | CYP19A1 (0.65) | CA1CA2CA7CA9CA14 | |
| SCHEMBL660540 | 0.80 | TAAR1 (0.62) | TAAR1NR3C2MTNR1AMTNR1BHDAC1 | |
| SCHEMBL27772539 | 0.79 | GABRA1 (0.63) | TAAR1NR1H2NR1H3AOC3ABCB1 | |
| SCHEMBL3364226 | 0.79 | CYP19A1 (0.71) | TAAR1NR1H2NR1H3AOC3 | |
| SCHEMBL5685633 | 0.78 | ABCB1 (0.58) | TAAR1NR3C2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PARP1 654/4885TAAR1 1672/4885NR3C2 220/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PARP1 654/4885TAAR1 1672/4885NR3C2 220/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | PARP1 654/4885TAAR1 1672/4885NR3C2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.